CD163 Outperforms CD68 in Clear Cell Renal Cell Carcinoma: Clinicopathological and Prognostic Correlations

Key Points

• The study aims to evaluate the prognostic value of CD163 compared to CD68 in clear cell renal cell carcinoma (RCC).
• Analyzed the relationship between macrophage polarization and tumor characteristics in RCC.
• Examined CD163 and CD68 metrics alongside other clinical variables.
• Assessed the association of CD163 with necrosis and tumor size.
• CD163 metrics showed stronger associations with necrosis compared to CD68.
• CD163 retained independent prognostic value along with tumor size.
• Findings support the use of CD163 in risk assessment for RCC patients.